The independent source for health policy research, polling, and news.
81 - 100 of 461 Results
Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.
As federal health scientists await a potential takeover by RFK Jr. and other medical skeptics in the second Trump administration, some are preparing résumés or retirement papers.
Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
With Election Day rapidly approaching, abortion is gaining traction as a voting issue, according to public opinion polls. Meanwhile, states with abortion bans are reviving the lawsuit — dismissed by the Supreme Court on a technicality this year — that could roll back the availability of the abortion pill mifepristone. Sarah Karlin-Smith of the Pink Sheet, Rachel Cohrs Zhang of Stat, and Victoria Knight of Axios join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Tricia Neuman, senior vice president of KFF and executive director of its Program on Medicare Policy, about Medicare open enrollment and the changes to the federal program for 2025.
Poppy seeds contaminated with opioids can be used to make a deadly brew, a watchdog says.
For decades, the pulse oximeters used in hospitals, ambulances, and homes have underestimated the oxygen needs of darker-skinned patients. The FDA is preparing guidelines to fix that. But will the new rules go far enough?
KFF Health News gives readers a chance to comment on a recent batch of stories.
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
KFF Health News and California Healthline staff made the rounds on national and state media this week to discuss topical stories. Here’s a collection of their appearances.
With medical devices, recalls are not always what they seem. In some recalls, including some of the most serious, the FDA and the manufacturers let doctors and hospitals continue to use the devices.
Former President Donald Trump has distanced himself from a Heritage Foundation document that outlines positions on abortion and a range of other social issues. But Democrats view it as a window into the far right’s to-do list and a clear opening for political attack.
The Centers for Disease Control and Prevention promises better tests are being developed, but the episode points to vulnerabilities in the country’s defense against emerging outbreaks.
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology.
The Supreme Court has issued its final opinions for the 2023-24 term, including decisions affecting abortion access, the opioid epidemic, and how the federal government functions. In this special episode, Sarah Somers , legal director of the National Health Law Program, joins KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss how the justices disposed of the term’s health-related cases and what those decisions could mean going forward.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
In what will certainly be remembered as a landmark decision, the Supreme Court has overruled a 40-year-old precedent that gave federal agencies, rather than judges, the power to interpret ambiguous laws passed by Congress. Administrative experts say the decision will dramatically change the way key health agencies do business. Also, the court decided not to decide whether a federal law requiring hospitals to provide emergency care overrides Idaho’s near-total ban on abortion. Alice Miranda Ollstein of Politico, Victoria Knight of Axios, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
© 2026 KFF